Perception of side effects of oncological systemic therapy in patients with breast and gynecological cancers

Perception of side effects of oncological systemic therapy in patients with breast and gynecological cancers - KEM-GO-1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017766

Enrollment

150

Registered

2019-08-05

Start date

2015-11-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C56 C50

Interventions

Group 1: Patients with breast or ovarian cancer who are indicated for chemotherapy due to their tumor biology will be offered to participate in the study. After approval, the interview takes place. He

Eligibility

Sex/Gender

Female

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Age >18 years Initial chemotherapy treatment at the Department of Gynecology & Gynecologic Oncology of the Essen-Mitte Hospital for senological or gynecological tumors Willingness to participate in the study + signed consent form

Exclusion criteria

Exclusion criteria: Lack of German understanding Reading difficulties / illiteracy expected life duration of therapy <3 months

Design outcomes

Primary

Measure	Time frame
This prospective study aims to investigate how side effects of systemic therapy of patients with gynecologic malignancies are perceived and assessed / categorized in their significance.	—

Secondary

Measure	Time frame
Evaluation of perception of side effects and their importance in patients undergoing maintenance therapy • Evaluation of perception of side effects at different times of treatment	—

Countries

Germany

Contacts

Public ContactBeyhan Ataseven

Kliniken Essen Mitte

b.ataseven@kem-med.com004920117434531

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026